SURMOUNT-1: what the TZ2 obesity data showed

SURMOUNT-1 is the Phase 3 randomized trial published in the New England Journal of Medicine in 2022 that established TZ2 as a leading research compound for incretin-based body-weight modulation. The trial enrolled 2,539 adults with obesity (mean BMI 38) and randomized them across four arms: TZ2 5 mg, 10 mg, 15 mg, or placebo, administered subcutaneously once weekly for 72 weeks.

What the trial measured

Two co-primary outcomes:

1. Percentage change in body weight from baseline to 72 weeks
2. Proportion of participants achieving ≥5% body weight reduction at 72 weeks

Secondary measures included waist circumference, blood pressure, lipid panel, glucose, and a basket of metabolic markers.

Headline findings

Arm	Mean weight change at 72 weeks	≥5% reduction	≥20% reduction
Placebo	−3.1%	35%	3%
TZ2 5 mg	−15.0%	85%	27%
TZ2 10 mg	−19.5%	89%	40%
TZ2 15 mg	−20.9%	91%	50%

The dose-response curve is approximately linear through 10 mg, then begins to flatten between 10 and 15 mg — useful information for research designs deciding between mid- and high-dose arms.

Titration protocol

SURMOUNT-1 used a slow titration schedule: 2.5 mg weekly for 4 weeks, then +2.5 mg every 4 weeks until the target maintenance dose was reached. This 20-week titration was designed to manage gastrointestinal adverse events, which are the dominant tolerability signal for incretin agonists. Most published research protocols using TZ2 follow this titration pattern; bypassing it accelerates GI side effects significantly.

Adverse events

The most common events across all arms were gastrointestinal — nausea (24–33% in TZ2 arms vs. 9% placebo), diarrhea (19–23% vs. 7%), and constipation (11–17% vs. 6%). Most events were mild-to-moderate and occurred during titration. Discontinuation rates due to adverse events were 4–7% across TZ2 arms versus 2.6% in placebo.

What it implies for research

A few methodological takeaways:

• Dose matters more than commonly assumed. The gap between 5 mg and 15 mg in percentage reduction was ~6 percentage points — material when comparing arms.
• 72-week endpoints differ from 16- or 24-week endpoints. Effect size grows steadily through the first 60+ weeks. Short-duration research understates the achievable signal.
• Titration is non-negotiable. Research models that don't titrate produce muddier tolerability data and higher attrition.
• Placebo arms still lose weight. The placebo arm lost 3% — driven by trial-protocol behavioral changes (diet/activity counseling). Don't compare absolute TZ2 numbers to a no-intervention baseline.

Limitations of the trial

SURMOUNT-1 was conducted in adults without diabetes and excluded participants with HbA1c > 6.5%. The follow-up duration (72 weeks) is long for a Phase 3 weight trial but short for an obesity intervention — durability beyond 2 years was not characterized. Generalizability to populations with diabetes is captured in the parallel SURPASS series.

Notes

This is a research summary of published clinical data. It is not a recommendation for any specific research protocol or design. For research use only. Not for human or veterinary use.

Reference

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. NEJM 2022;387:205–216. PMID: 35658024